SynthesisThe clinical respiratory journal2022
Blood biomarkers associated with acute type II respiratory failure in COPD: A meta-analysis.
Synthesis in The clinical respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Blood biomarkers associated with acute type II respiratory failure in COPD: A meta-analysis.The clinical respiratory journal · 2022Pooled it
- Trial
- Analysis of influencing factors and construction of nomogram prediction model for pulmonary infection in patients with acute exacerbation of chronic obstructive pulmonary disease complicated with type II respiratory failure.Frontiers in medicine · 2026Article
- Prognostic Factors Affecting Mortality Among Patients Admitted to the Intensive Care Unit with Acute Hypoxemic Respiratory Failure.Diagnostics (Basel, Switzerland) · 2025Article
- Trends and management of acute respiratory failure in hospitalized patients: a multicenter retrospective study in South Korea.Acute and critical care · 2025Article
- Correlation between the neutrophil-to-lymphocyte ratio and the 90-day all-cause mortality in patients with acute respiratory failure: a retrospective analysis based on the MIMIC-IV Database.BMC cardiovascular disorders · 2025Article
- Clinical status and cytokine profiles in patients with asthma or chronic obstructive pulmonary disease vaccinated against influenza.PloS one · 2025Article
- The red blood cell distribution width to albumin ratio was a potential prognostic biomarker for acute respiratory failure: a retrospective study.BMC medical informatics and decision making · 2024Article
- Analysis of therapeutic effects on type II respiratory failure and impact on blood gas changes: high-flow nasal oxygen therapy vs. non-invasive positive pressure ventilation.American journal of translational research · 2024Article
- A Diagnostic Nomogram for Predicting Hypercapnic Respiratory Failure in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Article
- Clinical value of CD3American journal of translational research · 2024Article
- Identification of circRNA-associated ceRNA networks in peripheral blood mononuclear cells as potential biomarkers for chronic obstructive pulmonary disease.Bioscience reports · 2023Article
- Low Skeletal Muscle Mass and Clinical Outcomes in Chronic Obstructive Pulmonary Disease.Tuberculosis and respiratory diseases · 2023Article
- Analysis of the Prognostic Impact of Staged Nursing Interventions on the Treatment of Patients with COPD Combined with Type II Respiratory Failure.Applied bionics and biomechanics · 2022Article
- Chitosan-Coated Solid Lipid Nano-Encapsulation Improves the Therapeutic Antiairway Inflammation Effect of Berberine against COPD in Cigarette Smoke-Exposed Rats.Canadian respiratory journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to summarize the risk factors of type II respiratory failure in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD), to guide clinical treatment in time, and consequently reduce the serious impact of COPD on human health.
methodsFive databases were searched for relevant articles on risk factors of acute exacerbation of COPD combinate with type II respiratory failure. We calculated the standard mean difference (SMD), odds ratio (OR), and their 95% confidence interval (95% CI) utilizing a fixed-effect model or a random-effect model according to the level of heterogeneity.
resultsAs of 14 May 2021, 13 articles were included in our meta-analysis. The results showed that low albumin and uric acid levels were the risk factors for type II respiratory failure in acute exacerbation of COPD patients, and the differences were statistically significant (albumin: SMD = -2.03, 95% CI: -2.81, -1.26; uric acid: SMD = -1.28, 95% CI: -1.41, -1.15). Besides, 10 other systematic markers have been reported to be the risk factors for type II respiratory failure of patients with acute exacerbation of COPD, but only in single study.
conclusionThe meta-analysis results further confirm that low albumin and uric acid levels are risk factors for type II respiratory failure in acute exacerbation of COPD patients. Additionally, this analysis also summarizes many emerging inflammatory indicators, nutritional indicator, and cardiovascular system indicators to predict the progression of acute exacerbation of COPD to type II respiratory failure but only in single study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.